NCT07513285

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-08-06Est. Completion: 2027-09-29

Enrollment target: 20 participants

Locations

UC Davis Medical Center, Sacramento, California, United States
Gastroenterolgy Center of Conneticut, Hamden, Connecticut, United States
Florida International Medical Research, Coral Gables, Florida, United States
L&A Morales Healthcare, Inc, Hialeah, Florida, United States
San Marcus Research Clinc, Inc, Miami Lakes, Florida, United States
Belis Delgado, MD PA, Miami Springs, Florida, United States
Infectious Disease Consultants of Georgia, Athens, Georgia, United States
Snake River Research PLLC, Idaho Falls, Idaho, United States
Endevour Health, Skokie, Illinois, United States
Newton-Wellesley Hospital, Newton, Massachusetts, United States
University of Massachusetts Memorial Healthcare, Worcester, Massachusetts, United States
Henry Ford Hospital, Detroit, Michigan, United States
DiGiovanna Institute for Medical Education and Research, Massapequa, New York, United States
Romano, Pontzer & Associated, Pittsburgh, Pennsylvania, United States
University of Utah, Salt Lake City, Utah, United States

Leukemia, Lymphocytic, AcuteLeukemia, Myeloid, AcuteLymphomaClostridium Difficile InfectionSolid Cancers

The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduc…

Aurora, United StatesCompleted Jul 2, 2025

Clostridioides Difficile Infection

The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioid…

Phoenix, United StatesEst. completion Apr 20, 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.